公开(公告)号：EP3391883A1

公开(公告)日：2018-10-24

申请号：EP16875807.6

申请日：2016-12-16

Applicant: Link Genomics, Inc. ,  Rohto Pharmaceutical Co., Ltd.

Inventor： NIWA, Shinichiro ,  OGURA, Dai ,  MIZUNUMA, Hidemi ,  ARAI, Yoko ,  KUROSE, Takahiro ,  TAKAI, Yoshihiro ,  MITSUGUCHI, Yoko ,  MORIYA, Mariyo

IPC: A61K31/421 ,  A61K31/192 ,  A61K31/38 ,  A61K31/404 ,  A61K31/41 ,  A61K31/426 ,  A61K31/436 ,  A61K31/47 ,  A61K45/00 ,  A61P27/02 ,  A61P43/00

CPC classification number: G01N33/5023 ,  A61K31/192 ,  A61K31/38 ,  A61K31/404 ,  A61K31/41 ,  A61K31/421 ,  A61K31/426 ,  A61K31/436 ,  A61K31/47 ,  A61K45/00 ,  A61K45/06 ,  A61K2300/00 ,  A61P27/02

Abstract: The existent therapeutic drugs for CNV are merely pharmaceuticals for a symptomatic therapy, and therapeutic drugs for radical cure are strongly demanded. Also, a therapeutic drug for Dry AMD does not exist, and therapeutic drugs for radical cure are strongly demanded. The present invention provides a prophylactic and/or therapeutic agent for choroidal neovascularization, containing a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient. Also, the present invention provides a drusen suppressor comprising a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient.